Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 9/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25663129 | 0.86 | CLK1 (0.41) | TDO2LIMK1EGFRPIK3CAPIK3CD | |
| SCHEMBL25663161 | 0.85 | LIMK1 (0.41) | LIMK1CDK5CDK5R1EGFRHTR2C | |
| SCHEMBL25663119 | 0.84 | TDO2 (0.40) | TDO2EGFRPIK3CAPIK3CDPIK3CB | |
| SCHEMBL25663160 | 0.83 | LIMK1 (0.42) | LIMK1CDK5CDK5R1EGFRHTR2C | |
| SCHEMBL25663163 | 0.83 | LIMK1 (0.39) | LIMK1CDK5CDK5R1EGFRHTR2C | |
| SCHEMBL25663149 | 0.82 | LIMK1 (0.40) | TDO2LIMK1CDK5CDK5R1EGFR | |
| SCHEMBL25663148 | 0.82 | LIMK1 (0.38) | LIMK1CDK5CDK5R1EGFRHTR2C | |
| SCHEMBL25663150 | 0.82 | LIMK1 (0.39) | TDO2LIMK1CDK5CDK5R1EGFR | |
| SCHEMBL25663488 | 0.81 | LIMK1 (0.36) | TDO2LIMK1CDK5CDK5R1HTR2C | |
| SCHEMBL25663178 | 0.80 | TDO2 (0.40) | TDO2EGFRPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | TDO2 122/4885LIMK1 1044/4885CDK5 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.